Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take on virus-driven cancers in early trial

NCT ID NCT07306156

Recruiting now Disease control Sponsor: Zhimin Zhai Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment called GP350 CAR-T cells for people with blood cancers that are linked to the Epstein-Barr virus and have not responded to standard therapy. The treatment involves collecting a patient's own immune cells, modifying them to better target the cancer, and giving them back after a short course of chemotherapy. The goal is to see if the treatment can shrink tumors and clear the virus from the blood, while monitoring for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBV ASSOCIATED LYMPHOID NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Epstein-Barr virus-associated lymphoproliferative disorder lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EBV ASSOCIATED LYMPHOID NEOPLASMS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Second Affiliated Hospital of Anhui Medical University

    RECRUITING

    Hefei, Anhui, 230031, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••